Jump to comment:
- Page navigation anchor for RE: SAFETY OF CANNABIS-ASSOCIATED AIR CONTAMINANTS AND EMISSIONSRE: SAFETY OF CANNABIS-ASSOCIATED AIR CONTAMINANTS AND EMISSIONS
Hall expertly reviewed adverse public effects of cannabis legalization(1) but did not review the safe level of cannabis air emissions. It is early days of large cannabis outdoor farms and there will be exposure of vulnerable populations to cannabis emissions, exposing vulnerable populations to approximately 200 volatile organic compounds (VOCs)of cannabis(2, 3).
We did a medical literature review (November and December 2019) to determine the safe level of cannabis air emissions using search terms: “cannabis and safety”, “...and “...and ambient”, “...and asthma”, “...and air contaminant”, “...worker safety”, “...and children”.
Of 3800 publications, “Cannabis-and-children” yielded 1975 publications (one every 2 days the last 2 years), -and-genetics yielded 994, -and-safety 688, -and-asthma 88, -and-ambient 22, -and-air contaminant 21.
There were only 8 peer-reviewed publications on cannabis worker safety (Supplement). A recent Australian study noted “Little research has been undertaken on the exposure to inhalable organic dust and other bioaerosols”… “workers may also be exposed to… organic dusts, bioaerosols, pollen/allergens, volatile organic compounds, psychoactive substances (tetrahydrocannabinol [THC])), noise, and ultraviolet radiation”(4). Health effects of cannabis farming on cannabis workers clearly does not translate to safety and safe levels of cannabis air emissions for vulnerable populations.
A report by Public Health Ontario on can...
Show MoreCompeting Interests: DR. JAMES A. RUSSELL AB, MD, FRCPC PROFESSOR OF MEDICINE UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER, BC CANADA FINANCIAL DISCLOSURE (last 36 months) Dr. Russell reports patents owned by the University of British Columbia (UBC) that are related to the use of PCSK9 inhibitor(s) in sepsis and related to the use of vasopressin in septic shock. Dr. Russell is an inventor on these patents. Dr. Russell was a founder, Director and shareholder in Cyon Therapeutics Inc. and is a shareholder in Molecular You Corp. Dr. Russell reports receiving consulting fees in the last 3 years from: 1. Asahi Kesai Pharmaceuticals of America (AKPA)(developing recombinant thrombomodulin in sepsis). 2. SIB Therapeutics LLC (developing a sepsis drug). 3. Ferring Pharmaceuticals (manufactures vasopressin and developing selepressin). Dr. Russell is no longer actively consulting for the following: 4. La Jolla Pharmaceuticals (developing angiotensin II; Dr. Russell chaired the DSMB of a trial of angiotensin II from 2015 - 2017) - no longer actively consulting. 5. Grifols (sells albumin) - no longer actively consulting. 6. PAR Pharma (sells prepared bags of vasopressin) - no longer actively consulting. Dr. Russell reports having received an investigator-initiated grant from Grifols (entitled “Is HBP a mechanism of albumin’s efficacy in human septic shock?”) that was provided to and administered by UBC. Dr. Russell is a co-owner of 3048 Quennel Road, Nanaimo, near where there is planned outdoor cannabis farming.